Scientists found a cannabinoid-inspired drug that controls muscle spasticity without causing sedation

Multi-method approach including chemical synthesis, receptor binding assays, electrophysiology, tissue-based functional assays, and in vivo testing in the mouse experimental autoimmune encephalomyelitis (EAE) model of MS. Toxicological and safety studies were performed in both animals and humans.

Cannabis-based treatments for MS spasticity exist (Sativex) but cause sedation and intoxication through CB1 activation. This study identified a new target, the BKCa channel, discovered through cannabinoid-inspired drug design, that could control spasticity without these central nervous system side effects.

This is a case where cannabinoid science led to a completely unexpected discovery. Starting from the structure of anandamide, researchers found a compound that does not work through cannabinoid receptors at all but instead revealed a new mechanism for controlling neural excitability. The BKCa channel could become a drug target for spasticity and potentially other conditions involving excessive neural firing.

Preclinical study with limited human safety data at time of publication. The EAE mouse model does not fully replicate human MS spasticity. Whether the same BKCa-mediated effect translates to human neurons and spasticity remains to be confirmed in clinical trials. Long-term safety and efficacy data are not available.